Rapid Dose Therapeutics receives funding for product scale-up manufacturing and commercialization

Mike Edwards   

News Funding video

Mark Upsall (left), CEO and founder of Rapid Dose Therapeutics.

Canadian life sciences company Rapid Dose Therapeutics (RDT) has secured government funding of $400,000 from The National Research Council of Canada Industrial Research Assistance (NRC-IRAP), to support a project focused on commercial development and scale-up manufacturing of cannabis infused QuickStrip oral dissolvable film strips.

The funding will help Burlington, ON-based RDT augment product development as well as enhance its manufacturing competency while creating new jobs and training skilled technical employees.


“This grant funding award from NRC-IRAP will help support speed to market for RDT’s QuickStrip products and enable scale production capacity to supply global markets, demonstrate superior product performance for customers while strengthening the Company’s IP portfolio,” said Mark Upsdell, CEO and founder of Rapid Dose Therapeutics.

“We are honoured and grateful to receive funding support from the Canadian government to help us advance our business innovation and commercialization activities.”

Print this page


Stories continue below